171 related articles for article (PubMed ID: 30912047)
1. Conditional Gene Knockout in Human Cells with Inducible CRISPR/Cas9.
Snijders KE; Cooper JD; Vallier L; Bertero A
Methods Mol Biol; 2019; 1961():185-209. PubMed ID: 30912047
[TBL] [Abstract][Full Text] [Related]
2. The iCRISPR platform for rapid genome editing in human pluripotent stem cells.
Zhu Z; González F; Huangfu D
Methods Enzymol; 2014; 546():215-50. PubMed ID: 25398343
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-Mediated Mutagenesis of Human Pluripotent Stem Cells in Defined Xeno-Free E8 Medium.
Soh CL; Huangfu D
Methods Mol Biol; 2017; 1498():57-78. PubMed ID: 27709569
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-mediated gene knockout is insensitive to target copy number but is dependent on guide RNA potency and Cas9/sgRNA threshold expression level.
Yuen G; Khan FJ; Gao S; Stommel JM; Batchelor E; Wu X; Luo J
Nucleic Acids Res; 2017 Nov; 45(20):12039-12053. PubMed ID: 29036671
[TBL] [Abstract][Full Text] [Related]
5. Generating CRISPR-Cas9-Mediated Null Mutations and Screening Targeting Efficiency in Human Pluripotent Stem Cells.
Bower OJ; McCarthy A; Lea RA; Alanis-Lobato G; Zohren J; Gerri C; Turner JMA; Niakan KK
Curr Protoc; 2021 Aug; 1(8):e232. PubMed ID: 34432381
[TBL] [Abstract][Full Text] [Related]
6. Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.
Thamodaran V; Rani S; Velayudhan SR
Methods Mol Biol; 2022; 2454():755-773. PubMed ID: 33830454
[TBL] [Abstract][Full Text] [Related]
7. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.
Ihry RJ; Worringer KA; Salick MR; Frias E; Ho D; Theriault K; Kommineni S; Chen J; Sondey M; Ye C; Randhawa R; Kulkarni T; Yang Z; McAllister G; Russ C; Reece-Hoyes J; Forrester W; Hoffman GR; Dolmetsch R; Kaykas A
Nat Med; 2018 Jul; 24(7):939-946. PubMed ID: 29892062
[TBL] [Abstract][Full Text] [Related]
8. A lentivirus-free inducible CRISPR-Cas9 system for efficient targeting of human genes.
Bisht K; Grill S; Graniel J; Nandakumar J
Anal Biochem; 2017 Aug; 530():40-49. PubMed ID: 28477963
[TBL] [Abstract][Full Text] [Related]
9. Engineering Human Stem Cell Lines with Inducible Gene Knockout using CRISPR/Cas9.
Chen Y; Cao J; Xiong M; Petersen AJ; Dong Y; Tao Y; Huang CT; Du Z; Zhang SC
Cell Stem Cell; 2015 Aug; 17(2):233-44. PubMed ID: 26145478
[TBL] [Abstract][Full Text] [Related]
10. Targeting the AAVS1 Site by CRISPR/Cas9 with an Inducible Transgene Cassette for the Neuronal Differentiation of Human Pluripotent Stem Cells.
Gu J; Rollo B; Sumer H; Cromer B
Methods Mol Biol; 2022; 2495():99-114. PubMed ID: 35696030
[TBL] [Abstract][Full Text] [Related]
11. Optimized Cas9:sgRNA delivery efficiently generates biallelic MSTN knockout sheep without affecting meat quality.
Zhou S; Kalds P; Luo Q; Sun K; Zhao X; Gao Y; Cai B; Huang S; Kou Q; Petersen B; Chen Y; Ma B; Wang X
BMC Genomics; 2022 May; 23(1):348. PubMed ID: 35524183
[TBL] [Abstract][Full Text] [Related]
12. Conditional gene knockout and reconstitution in human iPSCs with an inducible Cas9 system.
Wu M; Liu S; Gao Y; Bai H; Machairaki V; Li G; Chen T; Cheng L
Stem Cell Res; 2018 May; 29():6-14. PubMed ID: 29554589
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Protocols for CRISPR/Cas9-based Gene Editing in Human Pluripotent Stem Cells.
Santos DP; Kiskinis E; Eggan K; Merkle FT
Curr Protoc Stem Cell Biol; 2016 Aug; 38():5B.6.1-5B.6.60. PubMed ID: 27532820
[TBL] [Abstract][Full Text] [Related]
14. [Efficient genome editing in human pluripotent stem cells through CRISPR/Cas9].
Liu GG; Li S; Wei YD; Zhang YX; Ding QR
Yi Chuan; 2015 Nov; 37(11):1167-73. PubMed ID: 26582531
[TBL] [Abstract][Full Text] [Related]
15. Developing CRISPR/Cas9-Mediated Fluorescent Reporter Human Pluripotent Stem-Cell Lines for High-Content Screening.
Vojnits K; Nakanishi M; Porras D; Kim Y; Feng Z; Golubeva D; Bhatia M
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458632
[TBL] [Abstract][Full Text] [Related]
16. Optimized inducible shRNA and CRISPR/Cas9 platforms for in vitro studies of human development using hPSCs.
Bertero A; Pawlowski M; Ortmann D; Snijders K; Yiangou L; Cardoso de Brito M; Brown S; Bernard WG; Cooper JD; Giacomelli E; Gambardella L; Hannan NR; Iyer D; Sampaziotis F; Serrano F; Zonneveld MC; Sinha S; Kotter M; Vallier L
Development; 2016 Dec; 143(23):4405-4418. PubMed ID: 27899508
[TBL] [Abstract][Full Text] [Related]
17. Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease.
Johnson MJ; Laoharawee K; Lahr WS; Webber BR; Moriarity BS
Sci Rep; 2018 Aug; 8(1):12144. PubMed ID: 30108345
[TBL] [Abstract][Full Text] [Related]
18. Pipeline for the Generation and Characterization of Transgenic Human Pluripotent Stem Cells Using the CRISPR/Cas9 Technology.
Mianné J; Bourguignon C; Nguyen Van C; Fieldès M; Nasri A; Assou S; De Vos J
Cells; 2020 May; 9(5):. PubMed ID: 32466123
[TBL] [Abstract][Full Text] [Related]
19. sgRNA Sequence Motifs Blocking Efficient CRISPR/Cas9-Mediated Gene Editing.
Graf R; Li X; Chu VT; Rajewsky K
Cell Rep; 2019 Jan; 26(5):1098-1103.e3. PubMed ID: 30699341
[TBL] [Abstract][Full Text] [Related]
20. Unpredicted central inversion in a sgRNA flanked by inverted repeats.
Wang G; Sukumar S
Mol Biol Rep; 2020 Aug; 47(8):6375-6378. PubMed ID: 32424520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
